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It is widely recognized that, in acute stroke, time is brain1 and that the earlier intravenous thrombolysis (IVT) treatment is 
administered, the better the outcome.2–4 Remarkably, inverse 
relationship between onset-to-door time (ODT) and door-to-
needle time (DNT) in stroke thrombolysis was previously 
addressed.5–11 According to these reports, every 10-minute 
raise in ODT increases the likelihood of receiving IVT within 
60 minutes from hospital admission (DNT) by ≈20%. These 
data come from nation-wide stroke unit registries,6 nation-wide 
general stroke population registries,9–11 and from International 
Stroke Thrombolysis Registries (ISTR),12 including centers 
with different levels of expertise in acute stroke care.
In this study, it was our intention to analyze the relationship 
between ODT and DNT in 10 dedicated stroke centers with 
a long tradition of acute stroke care, high volume of patients, 
and a proven track record of participating in acute stroke 
Background and Purpose—Inverse relationship between onset-to-door time (ODT) and door-to-needle time (DNT) in 
stroke thrombolysis was reported from various registries. We analyzed this relationship and other determinants of DNT 
in dedicated stroke centers.
Methods—Prospectively collected data of consecutive ischemic stroke patients from 10 centers who received IV thrombolysis 
within 4.5 hours from symptom onset were merged (n=7106). DNT was analyzed as a function of demographic and 
prehospital variables using regression analyses, and change over time was considered.
Results—In 6348 eligible patients with known treatment delays, median DNT was 42 minutes and kept decreasing 
steeply every year (P<0.001). Median DNT of 55 minutes was observed in patients with ODT ≤30 minutes, whereas it 
declined for patients presenting within the last 30 minutes of the 3-hour time window (median, 33 minutes) and of the 
4.5-hour time window (20 minutes). For ODT within the first 30 minutes of the extended time window (181–210 minutes), 
DNT increased to 42 minutes. DNT was stable for ODT for 30 to 150 minutes (40–45 minutes). We found a weak inverse 
overall correlation between ODT and DNT (R2=−0.12; P<0.001), but it was strong in patients treated between 3 and 
4.5 hours (R2=−0.75; P<0.001). ODT was independently inversely associated with DNT (P<0.001) in regression analysis. 
Octogenarians and women tended to have longer DNT.
Conclusions—DNT was decreasing steeply over the last years in dedicated stroke centers; however, significant oscillations 
of in-hospital treatment delays occurred at both ends of the time window. This suggests that further improvements can be 
achieved, particularly in the elderly.   (Stroke. 2013;44:2808-2813.)
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trials. Particularly, we explored whether DNTs are shortening 
steeper than elsewhere and whether dedicated stroke centers 
can abolish the inverse relationship between ODT and DNT.
Patients and Methods
Study Setting
This observational study is a joint project of 10 European stroke 
centers. The study was approved by the relevant authorities in each 
participating center if required. This study was approved in the co-
ordinating center (Helsinki) as a registry but did not require ethical 
board review.
Data from individual consecutive patients were collected with a 
standardized form with predefined variables. Local study investiga-
tors filled in the forms systematically using prospectively ascertained 
in-hospital thrombolysis registries. Completed forms from all centers 
were compiled in the coordinating center Helsinki, where the analyses 
of the pooled data were performed. The following prospectively ascer-
tained variables were used: age, sex, onset-to-treatment time (OTT), 
ODT, DNT, year of admission, baseline stroke severity evaluated by 
the National Institutes of Health Stroke Scale (NIHSS) score, vascular 
risk factors according to predefined criteria,13 and stroke mechanism 
according to the Trial of Org 10172 in Acute Stroke Treatment crite-
ria.14 All medical conditions refer to condition before index stroke. The 
baseline cohort comprised 7106 patients treated with IVT (Table 1), of 
whom we excluded patients who received IVT >5 hours from symp-
tom onset (n=369), patients with unknown treatment delays (n=324), 
and patients with in-hospital stroke (n=65). Hence, 6348 patients were 
eligible for the final analysis. Patients receiving intra-arterial or bridg-
ing therapies have not been included in the database.
The primary analysis was the relationship between ODT and DNT. 
Secondarily, we analyzed treatment delays according to sex, age, and 
baseline NIHSS. We also calculated DNT changes over years. Nearly 
all (>98%) patients were evaluated by examiners certified in NIHSS 
(video training in NIHSS).
Statistical Analyses
After data pooling, distribution was tested. Because of non-normal 
distribution of all treatment delays, age, and NIHSS, data are present-
ed as median and interquartile range (IQR). Groups were compared 
with the independent samples Mann–Whitney U or Kruskal–Wallis 
tests, as appropriate. Correlations were tested with Spearman test. 
A model of linear regression was constructed with DNT (continu-
ous data) as dependent parameter. The model included age, baseline 
NIHSS, sex, ODT by categories of 30 minutes, year of admission, 
and center. Condition index of eigenvalue was used to test multicol-
linearity (ie, a high degree of correlation among several independent 
variables). This commonly occurs in regression models with a large 
number of independent variables; some of them may measure the 
same phenomena. Because of multicollinearity, even small changes 
in the data produce wide changes in the parameter estimates, co-
efficients may have very high SE and low significance levels, and 
coefficients may have the incorrect sign or implausible magnitude. 
Values of condition index >15 were considered as having a possible 
problem with collinearity, whereas those with >30 as serious prob-
lem. Statistical significance was set at 0.05 (2-tailed). Analyses were 
performed on IBM SPSS 18 (IBM Corp; Armonk, NY).
Results
We observed a robust annual decrease of DNT (Figure 1A–
1C). Median DNT in the pooled cohort was 42 minutes (IQR, 
26–65), and >80% of all patients were treated within 3 hours 
from symptom onset. The rest of the baseline characteristics 
are shown in Table 2.
When analyzing DNT in 30-minute categories of ODT 
(Table 3), we observed the highest DNT in patients presenting 
within 30 minutes from symptom onset (median, 55 minutes; 
IQR, 35–75). Thereafter, DNT decreased and remained similar 
(median, 40–45 minutes) for ODT between 30 and 150 min-
utes, whereafter it decreased to a median of 33 minutes (IQR, 
20–58) for patients admitted within the last 30 minutes of 
the 3-hour time window. In the first 30 minutes (ODT 181–
210 minutes) of the extended time, window DNT rose back 
to a median of 42 minutes (IQR, 28–60) but decreased to 
20 minutes (IQR, 14–28) for patients presenting within the 
last 30 minutes of the 4.5-hour time window. There was no 
significant difference in mortality and frequencies of symp-
tomatic intracranial hemorrhage among the patients admitted 
close to the end of the time windows (3-hour and 4.5-hour, 
before and after European Cooperative Acute Stroke Study 
[ECASS]-III publication, respectively) compared with other 
ODT categories (data not shown).
Secondary analysis of DNT versus ODT was performed 
in strata of age, baseline NIHSS, and sex. Compared with 
moderate stroke severity (NIHSS 7–12), patients with mild 
(NIHSS 0–6) and severe (NIHSS >12) symptoms were treated 
slower when admitted within 30 minutes from symptom onset 
(P=0.03), whereas no other changes in DNT occurred (Table 3). 
Overall, patients older than 50 years of age had somewhat lower 
DNT than those younger than 50 years of age, but there was no 
difference in DNT delays in any ODT category among these 
Table 1. Contribution of Individual Centers and Basic Baseline Patient Characteristics
Center Country n (%) Age, y Baseline NIHSS OTT, min DNT, min
Barcelona Spain 226 (3.2) 77 (67–83) 7 (4–13) 139 (100–186) 54 (43–66)
Basel Switzerland 588 (8.3) 74 (61–81) 12 (8–17) 160 (135–195) 76 (59–99)
Bern Switzerland 307 (4.3) 70 (62–78) 7 (5–12) 180 (150–220) 85 (65–105)
Erlangen Germany 820 (11.5) 74 (65–82) 10 (5–15) 120 (90–180) 33 (23–50)
Heidelberg Germany 1270 (17.9) 74 (66–81) 11 (7–17) 135 (105–180) 45 (30–62)
Helsinki Finland 1836 (25.8) 69 (60–77) 8 (5–14) 118 (86–160) 26 (17–48)
Lausanne Switzerland 437 (6.1) 69 (58–78) 13 (8–19) 150 (110–180) 48 (35–65)
Lille France 591 (8.3) 71 (58–80) 12 (7–17) 148 (116–185) 55 (40–70)
St. Gallen Switzerland 164 (2.3) 74 (63–81) 8 (4–13) 160 (127–193) 60 (50–80)
Tampere Finland 867 (12.2) 71 (61–79) 8 (5–14) 128 (100–160) 42 (26–60)
Data are presented as median (interquartile range). DNT indicates door-to-needle time; NIHSS, National Institutes of Health Stroke Scale; 
and OTT, onset-to-treatment time.
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patients. Significantly longer DNT delays were observed for 
octogenarian patients (Table 4). Women were treated in a gen-
erally somewhat slower manner than men, and we observed a 
significant difference for sex-related delays in patients admitted 
between 121 and 150 minutes from symptom onset (P<0.01; 
Table 4). Overall, women were significantly (P<0.001) older 
than men median 75 (64–82) versus 70 (60–78).
In the whole cohort, we observed a significant but weak 
inverse correlation between ODT and DNT (R2=−0.12; 
P<0.001; Figure 2A). This was similar to the situation 
in patients treated within 3 hours (R2=−0.19; P<0.001; 
Figure 2B); however, there was a strong inverse correlation in 
patients treated between 3 and 4.5 hours (R2=− 0.75; P<0.001; 
Figure 2C). In linear regression analysis, we found an inverse 
association of ODT (nine 30-minute categories) with DNT: 
B regression coefficient of −2.95 (−3.48 to −2.41; P<0.001). 
Age (continuous and octogenarians), baseline NIHSS, and 
sex were not associated with DNT (P=0.90 [0.14], 0.45, and 
0.10, respectively). Belonging to a certain center was also 
associated with DNT (<0.001); however, a possible collin-
earity was noted (condition index of eigenvalue, 16.6). Year 
of treatment had very strong collinearity (condition index of 
eigenvalue >2500) and was excluded from the model.
Post–ECASS-III Aspects
In a population of patients treated with IVT within 3 hours from 
symptom onset, DNT decreased from a median of 45 minutes 
(29–66) before ECASS-III to 35 minutes (21–54) thereafter 
(P<0.001). In the case of patients with OTT 3 to 4.5 hours, DNT 
was reduced from a median of 70 (39–104) to 54 minutes (32–
85; P<0.001). Both before and after the ECASS-III publication, 
patients with an OTT of 3 to 4.5 hours were treated with larger 
delays compared with an OTT of <3 hours (P<0.001).
Discussion
Concerns were raised about acute stroke care and treatment 
decisions because several studies reported faster administra-
tion of IVT to patients who present later, whereas physicians 
wait much longer with their treatment decision in patients 
presenting very early.5–11 In other words, the decision takes 
time when we have time. Such phenomenon is not specific 
for thrombolysis, neurology, or for medicine. This is a gen-
eral rule that is known under the term Parkinson’s Law (see 
The Economist, November 19, 1955). In the current study, we 
looked at treatment delays in a pooled cohort of 6348 patients 
from 10 dedicated stroke centers, where we observed a con-
tinuous robust annual decrease (Figure 1) but also found an 
inverse, though weak, correlation between ODT and DNT. 
Most significant changes of DNT occurred in the first 30 min-
utes from symptom onset and in the last 30 minutes of the 
3-hour and of the extended time window (Table 3).
The oscillations in DNT observed in our pooled cohort 
are far away from those reported in the Safe Implementation 
of Thrombolysis in Stroke (SITS-ISTR),12 in which DNT 
Figure 1. Annual changes in door-to-needle time (DNT). A, Patients treated within 4.5 hours from symptom onset. B, Patients treated 
within 3 hours from symptom onset. C, Patients treated between 3 and 4.5 hours from symptom onset. There is a remarkable change 
in DNT per year of treatment in C, which is caused by ≥2 factors. C represents patients treated between 3 and 4.5 hours from symptom 
onset (ie, off-label before publication of European Cooperative Acute Stroke Study [ECASS]-III results [end of September 2008]). This 
means that the number of patients treated within this time window before ECASS-III was rather low (n=299), and even small changes 
could have caused larger changes. In addition, it shows that centers were performing off-label thrombolysis according to their own (vary-
ing) institutional standards. The European Medicines Agency granted conditional license for IV thrombolysis in 2002, when new centers 
started to deliver the thrombolysis, delays of which were longer in the beginning (effect of experience).
Table 2. Demographics and Baseline Characteristics
Parameter N=6348
Age, y 72 (61–79)
Women, n (%) 2920 (46.0)
Baseline NIH Stroke Scale, score 10 (6–15)
Onset-to-treatment time, min 135 (101–173)
Onset-to-door time, min 80 (59–116)
Door-to-needle time, min 42 (26–65)
Treated within 3 h, n (%) 5199 (81.9)
Treated before publication of ECASS-III, n (%) 3072 (48.4)
Medical history, n (%)
  Diabetes mellitus 1244 (19.6)
  Previous stroke 952 (15.0)
  Coronary heart disease 1244 (19.6)
  Atrial fibrillation 1885 (29.7)
  Hypertension 4405 (69.4)
  Dyslipidemia 2546 (40.1)
Etiology, n (%)
  Large artery 1047 (16.5)
  Cardioembolism 2825 (44.5)
  Small vessel disease 413 (6.5)
  Other determined 229 (3.6)
  Unknown, multiple, not studied 1835 (28.9)
Continuous data are presented as median (interquartile range). DNT indicates 
door-to-needle time; ECASS-III, European Cooperative Acute Stroke Study-III; 
NIH, National Institutes of Health; and OTT, onset-to-treatment time.
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was larger by an average of 61 minutes in patients with an 
ODT <30 minutes compared with those presenting in the last 
30 minutes of the time window. In our analysis, the corre-
sponding delay in average DNT was 20 minutes in the 3-hour 
time window and 38 minutes for the extended time window. 
Given that ≈10% of patients were treated between 3 and 4.5 
hours in that SITS-ISTR report, our average 20-minute delay 
corresponds roughly to a 61-minute delay in the SITS-ISTR. 
Furthermore, there was virtually no difference (average of 3.5 
minutes) in the delays of our patients presenting just before the 
3-hour time window and those presenting just after, whereas 
the corresponding number in SITS-ISTR was 21 minutes.
It was estimated that every 10-minute increase in ODT cor-
responds to ≈20% higher odds of the DNT being <60 min-
utes.6,8,9 Fluctuations in treatment delays were also reported 
in helicopter emergency transports,15 in which patients trans-
ferred directly to the thrombolysis-administering hospital had 
a median ODT of 90 (60–125) and a DNT of 45 (30–60) min-
utes; for patients transferred via another hospital, these delays 
were 175 (105–257) and 30 (10–68) minutes, respectively. A 
relieving and important finding in our analysis is that DNT 
remained similar (Table 3) in patients presenting between 30 
and 150 minutes and between 181 and 210 minutes, and oscil-
lations actually occurred at both ends of the time window. 
Higher delays for ultrarapidly presenting patients can per-
haps be explained by insufficient time available to prenotify 
the stroke center. Indeed, lack of prenotification was shown 
to negatively influence DNT.16 In addition, it is more chal-
lenging to go through electronic medical chart records in such 
patients.17 On the other hand, the very short DNT of 20 min-
utes in the latest time window segment shows the potential of 
improving DNT also in the other ODT segments.
In secondary analysis, patients with mild and most severe 
symptoms were treated slower than other patients when admit-
ted within 30 minutes from symptom onset, but not at later 
admission time-points. Other than a chance finding, this can, 
perhaps, be explained by the generally bad condition of those 
with severe symptoms on early arrival, which is probably more 
Table 3. Door-to-Needle Time According to Onset-to-Treatment Time Analyzed for the Whole Cohort and Per Baseline Stroke 
Severity
ODT
Whole Cohort Tertiles of Baseline NIH Stroke Scale
Median DNT, min Mean DNT, min 0 to 6 7 to 12 >12 P Value
Whole ODT range 42 (26–65) 49±30 42 (26–63) 41 (25–65) 44 (27–65) 0.15
≤30 min (n=220) 55 (35–75) 61±36 51 (33–71) 42 (30–75) 59 (42–78) 0.03
31 to 60 min (n=1627) 44 (26–71) 53±35 43 (27–70) 44 (26–73) 44 (26–70) 0.88
61 to 90 min (n=1903) 45 (27–68) 50±31 45 (25–69) 43 (26–67) 45 (28–67) 0.67
91 to 120 min (n=1173) 44 (27–61) 47±27 44 (28–63) 43 (25–60) 44 (27–60) 0.68
121 to 150 min (n=671) 40 (26–55) 44±25 37 (26–55) 41 (27–56) 40 (25–55) 0.79
151 to 180 min (n=378) 33 (20–58) 41±26 36 (20–58) 33 (21–65) 32 (20–50) 0.65
181 to 210 min (n=196) 42 (28–60) 45±23 44 (29–60) 40 (25–58) 42 (29–60) 0.95
211 to 240 min (n=127) 32 (21–45) 36±19 30 (20–47) 30 (22–46) 35 (29–45) 0.43
240 to 270 min* (n=53) 20 (14–28) 22±11 20 (14–28) 20 (9–32) 22 (16–29) 0.43
Data for the whole cohort are presented as median (IQR) and average±SD and as median (IQR) for subgroups of NIH Stroke Scale. P values refer to comparison of 
DNT delays in patients with different baseline stroke severity (NIH Stroke Scale tertiles) per ODT category. DNT indicates door-to-needle time; IQR, interquartile range; 
NIH, National Institutes of Health; and ODT, onset-to-door time.
*Includes 2 patients with ODT between 270 and 300 minutes.
Table 4. Door-to-Needle Time According to Onset-to-Treatment Time by Sex and Age
ODT (min) Men (n=3404)
Women 
(n=2944) P Value ≤50 y (n=624) >50 y (n=5724) P Value ≤80 y (n=4961) >80 y (n=1387) P Value
Whole ODT range 41 (25–64) 45 (27–65) 0.01 45 (28–67) 42 (26–65) 0.03 41 (25–64) 45 (30–66) <0.001
≤30 min (n=220) 52 (33–75) 57 (36–76) 0.26 53 (34–82) 55 (35–75) 0.69 55 (33–80) 54 (39–68) 0.95
31 to 60 min (n=1627) 43 (25–68) 45 (28–76) 0.11 45 (30–69) 43 (26–71) 0.36 44 (26–71) 44 (27–70) 0.80
61 to 90 min (n=1903) 43 (25–68) 45 (28–66) 0.27 47 (25–75) 44 (27–67) 0.20 43 (25–67) 48 (30–68) 0.02
91 to 120 min (n=1173) 42 (27–61) 45 (27–63) 0.25 49 (28–65) 43 (27–60) 0.16 42 (26–60) 46 (30–64) 0.04
121 to 150 min (n=671) 36 (26–54) 42 (30–59) <0.01 42 (29–52) 40 (26–56) 0.77 37 (25–52) 45 (31–64) <0.01
151 to 180 min (n=378) 34 (20–59) 32 (20–56) 0.63 27 (18–52) 33 (21–58) 0.38 32 (20–56) 44 (25–66) 0.02
181 to 210 min (n=196) 41 (26–60) 44 (28–60) 0.97 50 (34–77) 41 (27–60) 0.23 43 (26–60) 41 (29–60) 0.94
211 to 240 min (n=127) 32 (21–41) 33 (22–50) 0.78 35 (19–43) 32 (21–46) 0.91 31 (20–45) 35 (24–50) 0.38
240 to 270 min* (n=53) 20 (14–28) 21 (15–30) 0.82 28 (15–48) 20 (14–27) 0.36 20 (14–28) 21 (18–35) 0.81
Data are presented as median (interquartile range). P values refer to comparison of door-to-needle delays in women/men or younger/older patients per ODT category. 
ODT indicates onset-to-door time.
*Includes 2 patients with ODT between 270 and 300 minutes.
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stabilized at later time-points. Patients with mild symptoms 
may have longer treatment delays because of waiting for results 
of advanced imaging or wait-and-see approach. Although in-
hospital delays were more stable in octogenarian patients, they 
were longer compared with younger patients, reflecting per-
haps uncertainty of benefit in some centers (Table 4). Result of 
International Stroke Trial-318 will probably change the delays 
in both octogenarians and those with mild symptoms in the 
future. We must admit that it can be more time-consuming to 
obtain all the necessary information (eg, anamnesis, comorbid-
ity) in the elderly, and frequent lack of a partner to provide 
information is another obstacle. Our observation of tendency 
toward longer delays in women patients can be explained by 
their older age compared with men. For the same reason, they 
also have a higher likelihood of having older partners (com-
pared with men stroke patients) or being widows, both of 
which negatively influence rapid prenotification and obtaining 
anamnesis. Nonetheless, age, NIHSS, and sex were not asso-
ciated with DNT in regression analysis but were associated 
with ODT. There was a significant effect of the treating center, 
although possible collinearity was detected.
We observed an inverse correlation between ODT and 
DNT, but it was a rather weak correlation for the whole cohort 
and for patients treated in the 3-hour time window. It was 
actually mostly explained by treatment delays in patients who 
received IVT between 3 and 4.5 hours. Both SITS-ISTR12 and 
Get With The Guidelines Stroke database9 reported longer 
DNT for patients treated between 3 and 4.5 hours compared 
with 0 and 3 hours. This was also the case in our study. What 
makes the situation different is that there was no change in 
median DNT in SITS-ISTR after publication of the ECASS 
III,19 and only modest changes were reported by Get With 
The Guidelines Stroke database investigators: median DNT in 
patients treated within 3 hours decreased from 79 to 74 min-
utes and in patients treated within 4.5 hours from median 80 to 
76 minutes. In our analysis, the corresponding numbers were 
reduction from median 45 (29–66) to 35 minutes (21–54) and 
from 70 (39–104) to 54 minutes (32–85).
Our study has limitations. Even if it was not the aim of this 
study, we do not know how many patients have not received 
IVT because of late arrivals. But we can at least assume that 
some of the patients could not have been treated within the 
3-hour time window because of a contraindication that could 
not have been solved before the end of the time window (eg, 
high blood pressure, lack of information in aphasic patients, 
needing contact with family). Nowadays, with a longer time 
window, many of these patients can be given IVT because we 
have more time to overcome these pitfalls (eg, blood pres-
sure can be lowered). This inevitably leads to increased DNTs 
because it takes additional time. Only 4.5% of patients were 
excluded because of the missing treatment delays, and these 
data would probably not change the results. Another 5% of 
patients treated >4.5 hours from symptom onset are off-label 
patients; only 2 of them were treated between 4.5 and 5 hours 
from symptom onset. This means that the majority of off-
label decisions were done at much later time-points, mostly 
in Heidelberg and Erlangen centers, which deliver off-label 
thrombolysis based on, for example, MRI mismatch selection.
In conclusion, we found lower DNT when less time was 
available for thrombolysis, a finding that was particularly 
pronounced at the very extremes of the thrombolysis time 
window. Clearly, there is still room for improving DNT, in 
particular for rapidly presenting patients. Of utmost impor-
tance, a continuous robust decrease in DNT over the years 
was observed, showing the importance and effects of targeted 
prehospital and emergency room measures to reduce DNT.17,20
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